Annovis Bio announces publication of new article in Biomolecules on buntanetap

Annovis Bio (ANVS) announced the publication of a new article in a peer-reviewed journal Biomolecules, which describes the pharmacokinetic, PK, profile of a new crystal form of buntanetap and compares it to the old form across several studies including mice, dogs, and humans. The new crystal buntanetap is currently being used in the pivotal Phase 3 clinical trial in patients with early AD, which is actively enrolling participants across the U.S. The study is designed to deliver two key readouts: symptomatic and disease-modifying. Moreover, this new form extends the intellectual property protection of the Company’s lead compound into the 2040s, covering its mechanism of action, therapeutic use, and combination with other drugs.